Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Study results are based on Surveillance, Epidemiology, and End Results-Medicare data for 166,581 patients receiving surgery or radiation for localized prostate cancer.

Telix Pharmaceuticals meets its FY25 revenue target with strong Q4 growth, expanded U.S. launches and ongoing trials.

External beam radiotherapy (EBRT) is a cornerstone of cancer treatment, with ongoing advances in imaging, motion management, ...

Ernie Strauss and Ronald Wakefield, who met through the patient navigation program of Northside Hospital, have built a support network to help other men navigate the prostate cancer landscape.

A surgeon at St. Clair Hospital in Mt. Lebanon recently performed the first HIFU procedure for prostate cancer at St. Clair using advanced new ultrasound technology. This makes St. Clair the first ...

Willy Goldschmidt, pictured with research radiographer, Vicky Sturgess, took part in a trial that cut radiotherapy doses for prostate cancer patients by three quarters A former prostate cancer patient ...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the first patient in the United States (U.S.) has been dosed ...

MELBOURNE, Australia, Jan. 17, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) has been dosed ...

MELBOURNE, Australia and INDIANAPOLIS, Jan. 16, 2026 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces that the first patient in the United States (U.S.) ...